Here's why the Resapp (ASX:RAP) share price closed 5% lower

The Resapp (ASX: RAP) share price closed 5% lower today after the company reported a loss in first-half FY21 results. Here's a closer look.

| More on:
falling asx share price represented by woman making sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resapp Health Ltd (ASX: RAP) share price spent today in the red after the company's 1HY21 results came out this morning.

Apparently, investors weren't impressed with the results and sent ResApp shares down 5.0% to close at 5.6 cents a share.

The company develops and commercialises its ResApp technology to provide healthcare solutions for respiratory disease. Let's review the results to decipher what pushed the ResApp share price down for the day.

ResApp Health posts first-half loss

For the period ended 31 December 2020, the healthcare solutions provider reported a net loss of $3.1 million compared to the $3.8 million loss posted for 1HY20.

ResApp's net asset position was $5.5 million.

At the end of 1HY21, ResApp Health's cash and cash equivalents totalled $4.2 million, a bump up from $3.9 million at the end of 1HY20.

Revenue totalled $46K and the company received $345,300 in government grants and tax incentives.

ResApp reported a 41 cent loss per share for 1HY21 compared to a 55 cent loss per share for 1HY20.

The company spent $1.7 million during 1HY21 on research and development activities pertaining to its medical technology. During 1HY20, it spent $2.8 million.

New appointment

ResApp also today advised the market that Mike Connell has been appointed as vice president (VP), commercial.

The company said Mr Connell brought extensive experience in sales, marketing and strategy across the industry. 

In his new position, he will process the company's growth strategy by pursuing a variety of international commercial activities. 

The company believes that Mr Connell's strong sector understanding and networks will present the business with new opportunities going forward.

During his time with GlaxoSmithKline (GSK),  Mr Connell launched and led GSK's European Established products business which delivered revenues totalling £3 billion during 2014.

He joins ResApp following time spent as general manager, corporate portfolio with Medibank.

About the ResApp share price

The ResApp share price has had a challenging past 12 months, crashing 74.5% over the period.

The company has a market capitalisation of $44.7 million and there are 758.1 million shares outstanding.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Market News

Why Aeris Resources, Netwealth, Nova Minerals, and Paragon Care shares are dropping today

These shares are under pressure on Friday. Let's find out why.

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Share Market News

Downer EDI wins $870m NZ highway maintenance contracts: What investors need to know

Downer EDI wins major New Zealand state highway maintenance contracts worth NZ$870 million, expanding its infrastructure portfolio.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Ord Minnett names 2 ASX 200 shares to buy for massive returns

The broker sees a lot of value in these big names. Here's what it is recommending.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »